Bio-Techne Corp has had a mixed financial journey over the recent quarters, experiencing dips and gains while encountering industry headwinds. The company's share estimating a potential upside of up to 32%. Further investment in Bio-Techne has been noted, with Focus Financial Network Inc. taking a $910,000 position. Partnership strategies have been initiated, with Nikon Instruments to expand access to innovative tech, and a recent collaboration with Regulus to announce top-line biomarker data. Bio-Techne also made headlines with the announcement of over 10,000 peer-reviewed publications citing their RNAscope Technology. Demonstrating a commitment to legal protection of their products, they filed a patent infringement lawsuit against Molecular Instruments. Despite a mixed fiscal Q2 2024, they succeeded in securing investment from the likes of S&CO Inc. while also facilitating board appointments and talent acquisition. After undertaking some strategic acquisitions such as Lunaphore, they further cemented their position in the biotech industry. However, the price decrease owing to downgrades by Citigroup put a dent in otherwise strong progress.
Bio-Techne Corp TECH News Analytics from Thu, 01 Oct 2020 07:00:00 GMT to Sat, 01 Jun 2024 17:02:17 GMT -
Rating -1
- Innovation 7
- Information 9
- Rumor 3
